Teva JV Allows Takeda To Offload Mature Japan Portfolio
This article was originally published in PharmAsia News
Executive Summary
Takeda is to transfer the bulk of its mature products in Japan into a new joint venture with Teva, in a move that will allow the Japanese firm to focus on its innovative portfolio while boosting the Israeli generic giant’s reach in Japan's fast-growing generics sector.